glp-1 news today nov 2025 november ISPOR 2025: Exploring reasons for GLP-1 discontinuation GLP-1 Weight Loss Drug Enforcement

Unrealised Expectations Despite progress, several anticipated 2025 milestones did not come to fruition: Regulatory progress stalled: FDAs obesity drug guidance, published in draft form in January 2025, remains unfinalised, whilst EMA has yet to update its 2016 guideline

1.(Wegovy) Glucagon-like peptide-1 RA (GLP-1 RA) 2.DPP-4

This can allow the body to burn more calories throughout the day to help eliminate stored fat

Both ligands had similar cAMP potency but the exendin-4-C16 showed 2.5-fold bias towards G protein recruitment and a 60% reduction in -arrestin-2 recruitment efficacy compared to exendin-4, as well as reduced GLP-1R endocytosis and preferential targeting towards recycling pathways

This blog discusses the Best Foods to Eat and Avoid When Taking a GLP-1 Medication

GLP-1 medications have transformed weight management for millions, but access remains a barrier for many